COMPANY

Presage Biosciences

HQ: Seattle, WA source · presagebio.com ↗ · West Coast

Keywords: oncology cancer tumors Head and Neck Squamous Cell Carcinoma Lymphoma Soft Tissue Sarcoma Head and Neck Cancer HNSCC Soft Tissue Sarcoma Adult AZD9592 MVC-101 Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them

Location: Seattle, WA · source · Oct 14, 2026

Profile checked Oct 10, 2026

9Trials (company is sponsor)8NIH grants

Timeline

May 22, 2024 Trial start Early phase 1: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC source ↗
Jun 1, 2022 Trial start Early phase 1: PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS source ↗
Oct 15, 2021 Trial start Early phase 1: Intratumoral Microdosing of Motolimod in HNSCC source ↗
Sep 15, 2021 Trial start Early phase 1: CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia source ↗
Jul 26, 2021 Trial start 0: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies source ↗
Jul 26, 2021 Trial start Early phase 1: PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC source ↗
Oct 7, 2020 Trial start Early phase 1: Intratumoral Microdosing of TAK-981 in Head and Neck Cancer source ↗
Dec 15, 2016 Trial start Phase 1: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma source ↗
2012-11 Trial start Phase 1: Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents source ↗

Upcoming milestones

2031-12 (ESTIMATED) · 0 · Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies · NCT04541108

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT06366451	PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC	Early phase 1	Completed	May 22, 2024	Mar 25, 2026 (actual)
NCT04541108	Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies	0	Active, not recruiting	Jul 26, 2021	2031-12 (estimated)
NCT06413095	PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS	Early phase 1	Completed	Jun 1, 2022	Jun 22, 2023 (actual)
NCT06062602	PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC	Early phase 1	Completed	Jul 26, 2021	Nov 15, 2022 (actual)
NCT04065555	Intratumoral Microdosing of TAK-981 in Head and Neck Cancer	Early phase 1	Completed	Oct 7, 2020	Jun 20, 2022 (actual)
NCT04891718	CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia	Early phase 1	Withdrawn	Sep 15, 2021	Jun 5, 2022 (actual)
NCT04272333	Intratumoral Microdosing of Motolimod in HNSCC	Early phase 1	Terminated	Oct 15, 2021	Mar 25, 2022 (actual)
NCT03056599	Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma	Phase 1	Completed	Dec 15, 2016	Jul 22, 2021 (actual)
NCT01831505	Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents	Phase 1	Completed	2012-11	2013-07 (actual)

NIH awards 8

Annual award amounts. Total $4.7M.

Aug 17, 2018 NIH award 5R44CA144104-06 FY2018: $943,738 awarded for that fiscal year; activity R44 (SBIR); PI KLINGHOFFER, RICHARD; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Arrayed drug microinjection for gui source ↗
Aug 22, 2017 NIH award 5R44CA144104-05 FY2017: $1,002,741 awarded for that fiscal year; activity R44 (SBIR); PI KLINGHOFFER, RICHARD; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Arrayed drug microinjection for g source ↗
Sep 1, 2016 NIH award 2R44CA144104-04 FY2016: $1,053,521 awarded for that fiscal year; activity R44 (SBIR); PI KLINGHOFFER, RICHARD; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Arrayed drug microinjection for g source ↗
Jun 23, 2014 NIH award 5R43CA171366-02 FY2014: $143,975 awarded for that fiscal year; activity R43 (SBIR); PI KLINGHOFFER, RICHARD; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Gene traps and in vivo microinjecti source ↗
Jun 17, 2013 NIH award 1R43CA171366-01A1 FY2013: $144,717 awarded for that fiscal year; activity R43 (SBIR); PI KLINGHOFFER, RICHARD; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Gene traps and in vivo microinjec source ↗
Apr 27, 2012 NIH award 5R42CA144104-03 FY2012: $652,762 awarded for that fiscal year; activity R42 (STTR); PI OLSON, JAMES M; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Sideport Needle Array Technologies for Pr source ↗
Jul 1, 2011 NIH award 4R42CA144104-02 FY2011: $544,375 awarded for that fiscal year; activity R42 (STTR); PI OLSON, JAMES M; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Sideport Needle Array Technologies for Pr source ↗
Jun 29, 2010 NIH award 1R42CA144104-01 FY2010: $164,492 awarded for that fiscal year; activity R42 (STTR); PI OLSON, JAMES M; recipient as written: PRESAGE BIOSCIENCES, INC., SEATTLE, WA. Sideport Needle Array Technologies for Pr source ↗